Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Appili Therapeutics Inc. (T:APLI)

Business Focus: Bio Therapeutic Drugs

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for APLI within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 02, 2021 06:01 ET
Appili Therapeutics to Host Drs. Scott Gottlieb and Syra Madad in Virtual Fireside Chat Discussing COVID-19: What We’ve Learned About Pandemic Responses, and Where We Go From Here
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced additional details on its webinar series examining major trends in the global infectious disease landscape. The first event, scheduled for March 3 at 1:00 p.m. ET, will feature Dr. Scott Gottlieb, Dr. Syra Madad, and Dr. Josh Schimmer. The panel will discuss the need for investing in an arsenal of treatments, preventatives, and public health policies as part of pandemic response planning.
Read full article
Feb 25, 2021 08:00 ET
Appili Therapeutics to Host Drs. Scott Gottlieb and Syra Madad in Virtual Fireside Chat Discussing COVID-19: What We’ve Learned About Pandemic Responses, and Where We Go From Here
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced additional details on its webinar series examining major trends in the global infectious disease landscape. The first event, scheduled for March 3 at 1:00 p.m. ET, will feature Dr. Scott Gottlieb, Dr. Syra Madad, and Dr. Josh Schimmer. The panel will discuss the need for investing in an arsenal of treatments, preventatives, and public health policies as part of pandemic response planning.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
23.40
15.17
Price to Book - most recent quarter
3.46
7.12
4.43
Price to Cash Flow per share - TTM
--
37.10
15.66
Price to Free Cash Flow per share - TTM
--
--
28.14
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Feb 28, 202144,774-14,390
Feb 15, 202159,16439,399
Jan 31, 202119,7651,370
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Appili Therapeutics Inc is a Canada-based pharmaceutical company. The Company is focused on the acquisition and development of treatments targeting infectious disease. The Company is focused on building and advancing adverse portfolio of anti-infective programs. The Company's anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is a clinical-stage antifungal candidate in development for severe and difficult-to-treat invasive fungal infections. The ATI-1701 is a vaccine candidate for tularemia. The ATI-1503 is a drug discovery program aimed at generating a class of antibiotics with broad spectrum activity against gram-negative superbugs. The ATI-1501 employs its taste-masked, oral-suspension technology with metronidazole for the patients with difficulty swallowing.

See business summary

 

Twitter

Search (past week) for $APLI.CA

  • No tweets found